COGNITIVE-SYSTEMS
Cognitive Systems Corp. announced today an integration with Airties to offer its patented WiFi Motion technology across Airties’ portfolio of WiFi 6 solutions. Cognitive’s WiFi Motion will make it easier than ever for service providers to access this revolutionary sensing technology.
Over the past six years, Cognitive Systems has designed, developed, and implemented the first and most sophisticated WiFi-enabled motion sensing software on the market. WiFi Motion leverages connected IoT devices to turn the entire home into a motion-sensing network, introducing an innovative way to use WiFi. With 37 ISPs currently offering WiFi Motion around the globe, millions of homes already have access to this new service and its growing number of applications.
“Service providers are looking for new ways to differentiate from competitors and retain customers. Our priority is providing smart WiFi solutions that offer value beyond connectivity,” said Taj Manku, Co-Founder and CEO of Cognitive Systems. “Like us, Airties aims to shape the next generation of wireless solutions and see the possibilities for motion sensing, from smarter home monitoring to a higher standard of eldercare. We’re doing the legwork with their Wi-Fi 6 portfolio to get WiFi Motion ready for some forward-thinking Airties service providers who want to offer these benefits to their customers as soon as possible.”
Cognitive Systems and Airties share a commitment to staying ahead of the market, both by being active members of the Wireless Broadband Alliance (WBA) and closely following emerging trends. In addition to the current home monitoring capabilities, WiFi Motion’s highly anticipated eldercare solution will bring peace of mind to caregivers by providing discreet wellness monitoring without the need for cameras or wearable devices. The market for remote wellness monitoring products is growing rapidly. Soon customers will be able to receive notifications and gain valuable insights into not only their homes but also the homes of loved ones.
“As a pioneer and leader in Wi-Fi sensing, we are pleased to be working with Cognitive Systems on new Wi-Fi 6 solutions,” said Metin Taskin, Co-Founder and CTO of Airties. “Cognitive’s product roadmap has a realistic game plan for both implementation and longevity. The integration of WiFi Motion and Airties can enable service providers to offer innovative value-add Wi-Fi services to their customers.”
About Cognitive Systems
Cognitive Systems Corp. is on a mission to transform the way WiFi networks are used. Its flagship technology, WiFi Motion™, uses wireless signals to sense motion in the home. WiFi Motion harnesses artificial intelligence and predictive analytics to reliably identify and localize motion for the smart home, home monitoring, and wellness monitoring markets. This patented technology is layered onto existing WiFi networks without additional hardware to enhance service provider and router manufacturer offerings.
www.cognitivesystems.com
https://www.linkedin.com/company/cognitive-systems-corp-/
About Airties
Founded in 2004, Airties is the most widely deployed provider of managed in-home Wi-Fi solutions to operators around the globe. The company offers Smart Wi-Fi software, a cloud-based management platform, and Mesh extenders. Service providers turn to Airties for the design, implementation, and ongoing optimization of their customers’ broadband experience. With an installed base of over 30 million homes, Airties’ customers include: Altice USA, AT&T, Singtel, Sky, Telia, Telstra, and many others. More information is available at www.Airties.com
.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210310005132/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
4Moving Biotech Receives FDA IND Clearance for 4P004, Strengthening Its Position as a Leading Innovator in Disease-Modifying Osteoarthritis Therapeutics8.1.2026 07:30:00 CET | Press release
FDA IND clearance enabling the worldwide expansion of the INFLAM MOTION Phase 2a trial, involving major U.S. sites Advancing the first clinical proof of concept in OA with a first-in-class intra-articular GLP-1 agonist A holistic clinical strategy design establishing the foundation for a future accelerated approval pathway 4Moving Biotech (4MB), a clinical stage biotechnology company developing next-generation, disease-modifying therapies for osteoarthritis (OA), today announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for 4P004, enabling the expansion of the Phase 2a INFLAM MOTION clinical trial into the United States (US). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260107798042/en/ 4Moving Biotech (4MB), a clinical stage biotechnology company developing next-generation, disease-modifying therapies for osteoarthritis (OA), today announced that the U.S. F
Organon Enters into a Commercialization Agreement for Daiichi Sankyo’s Nilemdo®in France, Denmark, Iceland, Sweden, Finland and Norway8.1.2026 07:30:00 CET | Press release
The agreement builds on Organon’s cardiovascular disease portfolio, leveraging expertise to expand access to new treatments for patients with dyslipidemia, especially statin-intolerant patients.This collaboration addresses a critical gap in care that disproportionately affects women, who are at a 47% higher risk of developing statin intolerance compared to men.i Organon today announced that it has entered into an agreement with Daiichi Sankyo Europe to commercialize Nilemdo® (bempedoic acid) in France, Denmark, Iceland, Sweden, Finland and Norway. Nilemdo® is a new, first-in-class drug indicated for patients with high cholesterol and cardiovascular disease risk. It provides an alternative treatment for patients that cannot be treated effectively with statins.ii “This collaboration combines Organon’s commercial agility with Daiichi Sankyo’s expertise in cardiovascular innovation to bring Nilemdo® to patients in France, Denmark, Iceland, Sweden, Finland and Norway,” says Thibault Crosnie
Prodapt Earns ISO 42001 Certification, the New Global Benchmark for Responsible Enterprise AI8.1.2026 07:00:00 CET | Press release
Prodapt today announced that it has been awarded the ISO 42001 certification, the world’s first and the only global standard for AI Management Systems (AIMS). Marking a significant milestone in its journey, Prodapt is setting a higher benchmark to deliver secure, ethical, and scalable AI for global enterprises. ISO 42001 lays a rigorous framework for governing AI across strategy, technology, and operations. The certification, awarded by an independent accredited body, validates Prodapt’s enterprise-grade AI management framework, including executive-led oversight, strong technology foundations, and disciplined operational processes. These measures ensure AI systems are responsibly designed, deployed, monitored, and evolved throughout their lifecycle. The evaluation emphasizes risk management, ethical AI practices, transparency, and scalability, confirming Prodapt’s ability to proactively identify and mitigate risks while ensuring accountability in AI-driven outcomes. Human-in-the-loop c
Azafaros to Present at J.P. Morgan’s 44th Annual Healthcare Conference8.1.2026 07:00:00 CET | Press release
Azafaros, a company building a portfolio to become a leader in lysosomal storage disorders with the goal of addressing neurological symptoms, today announced that it will present at J.P. Morgan’s 44th Annual Healthcare Conference on Thursday, January 15. The company’s presentation will begin at 9:30 am PT/12:30 am ET/6:30 am CET. The presentation will focus on the company’s lead product, nizubaglustat, a potential treatment for rare lysosomal storage disorders with neurological involvement including GM1/GM2 gangliosidoses and Niemann-Pick type C disease ((NPC). Two pivotal Phase 3 studies investigating nizubaglustat in GM1/GM2 gangliosidoses and NPC are currently enrolling, with data expected in 2027. The studies build on positive data from a robust clinical program including the Phase 2 RAINBOW study and the PRONTO natural history study. The Phase 3 studies are financed following the company’s successful completion of €132 million series B round completed in 1H 2025. About nizubaglust
Zilch to Acquire Fjord Bank to Kickstart European Expansion8.1.2026 01:40:00 CET | Press release
Acquisition will provide Zilch, the UK and EMEA’s fastest-growing fintech unicorn, with a European banking licence as it eyes international rollout Zilch, the consumer payments platform powering the future of commerce, today announces it has signed an agreement to acquire AB Fjord Bank, a Lithuania-based bank with approx. $120M in total assets that is authorised and regulated by the Bank of Lithuania and the European Central Bank. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260107714872/en/ Zilch to Acquire Fjord Bank to Kickstart European Expansion The acquisition will represent a major strategic milestone for Zilch, providing a European banking licence that will enable the accelerated rollout of its offering across Europe. Zilch will purchase 100% of Fjord Bank and will establish Lithuania as its European headquarters as a consequence of the transaction, using Vilnius as its operational and regulatory platform for expan
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom